Life Sciences Partners, Ysios Capital, Kurma Partners and VI Partners participated in a €10.35m series-D funding round for Xeltis.
LSP, which led the round, is currently investing from its Life Sciences Partners VI fund, which closed on €410m in November 2018.
The fresh capital will finance the company's vascular and valve trial programmes.
The company's technology is currently in clinical trials in the EU, Asia and in the US, with 28 patients receiving Xeltis devices to date.
In 2012, Xeltis merged with Qtis/E.
LSP and Kurma led a €27m series-A for Xeltis in December 2014. VI Partners was already a shareholder at this stage and also took part in the financing.
All three investors also backed the company's €3m series-B in December 2015.
Ysios joined a consortium of investors to provide a €45m series-C funding round for the company in 2017. The round was led by an anonymous strategic investor and also included contributions from LSP, Kurma Partners and VI Partners.
Xeltis is a clinical-stage medical device company that has built a polymer-based technology designed to enable natural restoration of cardiovascular function. Founded in 2006 as a University of Zurich spinout, the company is headquartered in Zurich and employs around 40 people, according to LinkedIn.
Life Sciences Partners – Clemens van Blitterswijk (partner).
Xeltis – Eliane Schutte (CEO).
Managing director Craig Ferguson discusses accelerated deployment activity during the pandemic and plans to scale up the PE allocation by 2025
Fund has a target of $600m, which it plans to reach by next year, according to Kommersant
Existing investors including Institut Català de Finances also take part in the financing
Biotech company initially raised €12m in December 2018